

2019 Assembly Bill 647 (LRB -2010)

An Act to amend 961.385 (2) (cs) 1., 961.385 (5) (b) and 961.385 (6) (a) of the statutes; relating to: the prescription drug monitoring program. (FE)

2019

12-05.	A.	Introduced by Representatives Nygren, Plumer, Magnafici, Hutton, James, Petryk, Kolste, Sargent, Billings, Born, Snyder, Petersen, Kitchens, Quinn, Felzkowski, Edming, Kulp, Rohrkaste, Knodl, Tusler, Duchow, Dittrich, Tranel, Thiesfeldt, Jagler, Spiros, Mursau, Ramthun, Pope, Doyle, Bowen and Spreitzer ; cosponsored by Senators Testin, Cowles, Olsen, Wanggaard, Schachtner and Marklein .	417
12-05.	A.	Read first time and referred to Committee on Substance Abuse and Prevention	417
12-10.	A.	Representative Wichgers added as a coauthor	422
12-13.	A.	Fiscal estimate received	

2020

01-07.	A.	Representative Stuck added as a coauthor	443
01-08.	A.	Public hearing held	
01-15.	A.	Executive action taken	
01-16.	A.	Report passage recommended by Committee on Substance Abuse and Prevention, Ayes 9, Noes 0	478
01-16.	A.	Referred to committee on Rules	478
01-16.	A.	Placed on calendar 1-21-2020 by Committee on Rules	
01-21.	A.	Read a second time	494
01-21.	A.	Ordered to a third reading	494
01-21.	A.	Rules suspended	494
01-21.	A.	Read a third time and passed	494
01-21.	A.	Ordered immediately messaged	494
01-22.	S.	Received from Assembly	604
01-27.	S.	Read first time and referred to committee on Senate Organization	616
01-27.	S.	Available for scheduling	
02-14.	S.	Public hearing requirement waived by committee on Senate Organization, pursuant to Senate Rule 18 (1m), Ayes 5, Noes 0	678
02-14.	S.	Placed on calendar 2-19-2020 pursuant to Senate Rule 18(1)	679
02-19.	S.	Senator Larson added as a cosponsor	
02-19.	S.	Read a second time	
02-19.	S.	Ordered to a third reading	
02-19.	S.	Rules suspended	
02-19.	S.	Read a third time and concurred in	
02-19.	S.	Ordered immediately messaged	
02-20.	A.	Received from Senate concurred in	639

MB



19en A. B-64.7

ENROLLED BILL

Adopted Documents

Original

Engrossed

Substitute Amdt

19 2010, 1

Amendments: None or Listed below.

Corrections: None or Listed by date below.

Topic: Same as relating clause or Indicated below.

2/29/20

Cabe

Date

Enrolling Drafter



State of Wisconsin
2019 - 2020 LEGISLATURE

LRB-2010/1
MED:cdc

2019 ASSEMBLY BILL 647

December 5, 2019 - Introduced by Representatives NYGREN, PLUMER, MAGNAFICI, HUTTON, JAMES, PETRYK, KOLSTE, SARGENT, BILLINGS, BORN, SNYDER, PETERSEN, KITCHENS, QUINN, FELZKOWSKI, EDMING, KULP, ROHRKASTE, KNODL, TUSLER, DUCHOW, DITTRICH, TRANEL, THIESFELDT, JAGLER, SPIROS, MURSAU, RAMTHUN, POPE, DOYLE, BOWEN and SPREITZER, cosponsored by Senators TESTIN, COWLES, OLSEN, WANGGAARD, SCHACHTNER and MARKLEIN. Referred to Committee on Substance Abuse and Prevention.

1 AN ACT *to amend* 961.385 (2) (cs) 1., 961.385 (5) (b) and 961.385 (6) (a) of the
2 statutes; **relating to:** the prescription drug monitoring program.

Analysis by the Legislative Reference Bureau

Current law requires the Controlled Substances Board to establish a Prescription Drug Monitoring Program (PDMP) that requires pharmacies and health care practitioners to generate records documenting the dispensing of monitored prescription drugs. Records from the PDMP may be disclosed to persons specified under current law or by the board by rule. This bill makes changes to certain requirements under the PDMP:

1. Subject to exceptions, current law requires that a patient's records under the program be reviewed before a practitioner issues a prescription order for the patient. However, current law provides that this requirement does not apply after April 1, 2020. The bill extends the application of this requirement by five years, to April 1, 2025.

2. Current law requires the board to conduct a quarterly review of the PDMP to evaluate the actual outcomes of the PDMP compared with projected outcomes. However, current law provides that this requirement does not apply after October 30, 2020. The bill extends the application of this requirement by five years, to October 30, 2025.

